Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Cash & Equivalents (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Cash & Equivalents for 16 consecutive years, with $6.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents rose 49.2% to $6.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.8 million, a 49.2% increase, with the full-year FY2024 number at $4.1 million, down 4.09% from a year prior.
  • Cash & Equivalents was $6.8 million for Q3 2025 at Harvard Bioscience, down from $7.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $7.8 million in Q4 2021 to a low of $3.8 million in Q1 2023.
  • A 5-year average of $5.2 million and a median of $5.1 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: surged 137.24% in 2021, then crashed 42.36% in 2022.
  • Harvard Bioscience's Cash & Equivalents stood at $7.8 million in 2021, then plummeted by 42.36% to $4.5 million in 2022, then decreased by 4.99% to $4.3 million in 2023, then fell by 4.09% to $4.1 million in 2024, then soared by 65.94% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Cash & Equivalents are $6.8 million (Q3 2025), $7.4 million (Q2 2025), and $5.5 million (Q1 2025).